PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $41,430,000 | +105859.1% | 1,500,000 | -11.8% | 2.32% | -9.9% |
| Q1 2023 | $39,100 | -98.5% | 1,700,000 | +344.9% | 2.58% | +1255.3% |
| Q2 2018 | $2,568,000 | -21.8% | 382,139 | 0.0% | 0.19% | -22.4% |
| Q1 2018 | $3,283,000 | -60.5% | 382,139 | -4.5% | 0.24% | -71.9% |
| Q4 2017 | $8,320,000 | -5.8% | 400,000 | -20.0% | 0.87% | -44.2% |
| Q3 2017 | $8,835,000 | +56.2% | 500,000 | 0.0% | 1.56% | +66.5% |
| Q2 2017 | $5,655,000 | -35.4% | 500,000 | -26.9% | 0.94% | -26.3% |
| Q1 2017 | $8,757,000 | -44.7% | 683,600 | -5.1% | 1.27% | -40.4% |
| Q4 2016 | $15,833,000 | -6.3% | 720,000 | -10.0% | 2.13% | +14.5% |
| Q3 2016 | $16,904,000 | – | 800,000 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |